Investor & Media
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma Cosa Mesa, Calif., December 11, 2023 (GlobeNewswire)...
AiViva BioPharma Appoints Les Kaplan, PhD, to the Board of Directors
AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors Costa Mesa, Calif.,...
AiViva BioPharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors
Costa Mesa, Calif., August 30, 2023 (GlobeNewswire) – AiViva Biopharma Inc., a clinical-stage biotechnology company...
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
Novel JEL™ Technology for Periocular Administration Costa Mesa, Calif., May 22, 2023 – AiViva Biopharma...
AiViva BioPharma Announces New Patent Received
Newport Beach, California – August 15, 2022 – AiViva Biopharma, a clinical-stage biopharmaceutical company has...
AiViva BioPharma is recognized by Life Sciences Review as Top 20 Clinical-Stage Biopharmaceutical Company for 2022
Life Sciences Review Recognizes AiVivaTop 20 Clinical-Stage Biopharmaceutical Companies of 2022Downdload PDF File > Life...
